Consequently, a higher level of sCTLA‐4 could reduce the inhibition of effector T cells by blocking B7/CTLA‐4 interaction, thereby decreasing de novo carcinogenesis and IHM incidence. This evidence concerns the gene CTLA4 and invasive hydatidiform mole.